Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar

Objectives: Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder responsive to immunomodulatory treatments. 10–20% of MGs are not responsive to conventional first-line therapies. Here, we sought to investigate the efficacy and safety of rituximab therapy in the treatment of patients w...

Full description

Bibliographic Details
Main Authors: Farzad Fatehi, Kamyar Moradi, Ali Asghar Okhovat, Ghazaleh Shojatalab, Behnaz Sedighi, Reza Boostani, Payam Sarraf, Bahram Haghi Ashtiani, Majid Ghasemi, Soussan Moussavi, Nassim Anjidani, Shahriar Nafissi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Neurology
Subjects:
clinical response
myasthenia gravis
refractory
rituximab
zytux TM
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.682622/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.682622/full

Similar Items